/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Sara Wiegmann

Bayer (Germany)(DE)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

6

Papers

95

Citations

5

h-index

5

i10-index

Sara Wiegmann is an academic researcher from Bayer (Germany). The author has contributed to research in topics: Hemophilia Treatment and Research & Virus-based gene therapy research & CRISPR and Genetic Engineering. The author has an h-index of 5, co-authored 6 publications.

ORCID: 0000-0002-9775-8373

Research Topics

Hemophilia Treatment and Research Virus-based gene therapy research CRISPR and Genetic Engineering CAR-T cell therapy research Catalytic Cross-Coupling Reactions

Papers by this author

works

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

2019 · Annals of Hematology · 29 citations

https://doi.org/10.1007/s00277-019-03747-2

Anita Shah Alexander Solms Sara Wiegmann Maurice J. Ahsman

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

2022 · Journal of Thrombosis and Haemostasis · 25 citations

https://doi.org/10.1111/jth.15744

Bettina Nowotny Dirk Thomas Stephan Schwers Sara Wiegmann

Research topics

topics

Hemophilia Treatment and Research

Virus-based gene therapy research

CRISPR and Genetic Engineering

CAR-T cell therapy research

Catalytic Cross-Coupling Reactions

Chat about Author

Papers

Chat

Click to start Chat